Meridian Bioscience Receives FDA Clearance for New Legionella Test
Meridian Bioscience, Inc. has received FDA clearance for TRU Legionella, a new rapid assay for detection of legionellosis. TRU Legionella is a rapid lateral flow device that provides optimized detection of Legionella pneumophila serogroup 1 that is most commonly associated with Legionnaire´s disease.The TRU Legionella test provides a much needed solution for an often under-diagnosed disease. Approximately 4 million to 5 million cases of community acquired pneumonia occur each year in the U.S. and Legionella is implicated in 5-8% of the cases. According to published statistics, incidence of Legionella cases has nearly tripled in the past decade and could be attributed to increase testing for disease. TRU Legionella empowers laboratories with an accurate, cost effective, and rapid result for Legionella detection.
Tags: Legionella, FDA, Legionella pneumophila
Date Published: March 5, 2012
Source article link: Meridian Bioscience » company contact details